PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 21733572-6 2011 From cellular uptake studies, the nanoparticles developed enhanced the intracellular DCT uptake in the CD44-overexpressing cell line (MCF-7). Docetaxel 85-88 CD44 molecule (Indian blood group) Homo sapiens 103-107 25648974-1 2015 In the attempt to develop novel concepts in designing targeted nanoparticles for combination therapy of cancer, we propose here CD44-targeted hyaluronan-decorated double-coated nanoparticles (dcNPs) delivering the lipophilic chemotherapeutic docetaxel (DTX) and an anionic porphyrin (TPPS4). Docetaxel 242-251 CD44 molecule (Indian blood group) Homo sapiens 128-132 25648974-1 2015 In the attempt to develop novel concepts in designing targeted nanoparticles for combination therapy of cancer, we propose here CD44-targeted hyaluronan-decorated double-coated nanoparticles (dcNPs) delivering the lipophilic chemotherapeutic docetaxel (DTX) and an anionic porphyrin (TPPS4). Docetaxel 253-256 CD44 molecule (Indian blood group) Homo sapiens 128-132 24643931-1 2014 PURPOSE: It is hypothesized that docetaxel (Doc)-loaded hyaluronic acid (HA)-polyethylene glycol/poly(epsilon-caprolactone)-grafted oily core nanocapsules (NCs) can enhance the drug cytotoxicity and uptake in CD44 expressing breast cancer (BC) cells (MDA-MB 231). Docetaxel 33-42 CD44 molecule (Indian blood group) Homo sapiens 209-213 24643931-1 2014 PURPOSE: It is hypothesized that docetaxel (Doc)-loaded hyaluronic acid (HA)-polyethylene glycol/poly(epsilon-caprolactone)-grafted oily core nanocapsules (NCs) can enhance the drug cytotoxicity and uptake in CD44 expressing breast cancer (BC) cells (MDA-MB 231). Docetaxel 44-47 CD44 molecule (Indian blood group) Homo sapiens 209-213 24444042-0 2014 CD44-targeted docetaxel conjugate for cancer cells and cancer stem-like cells: a novel hyaluronic acid-based drug delivery system. Docetaxel 14-23 CD44 molecule (Indian blood group) Homo sapiens 0-4 24444042-1 2014 A CD44-targeted macromolecular conjugate of docetaxel was prepared via a pH-sensitive linkage to hyaluronic acid and was characterized using NMR, gel permeation chromatography, and differential scanning calorimetry. Docetaxel 44-53 CD44 molecule (Indian blood group) Homo sapiens 2-6 24444042-4 2014 Hyaluronic acid-docetaxel conjugates showed specific toxicity only in CD44-expressing cells in vitro, along with a decreased risk of neutropenia and dose-dependent mortality in vivo. Docetaxel 16-25 CD44 molecule (Indian blood group) Homo sapiens 70-74 22870202-2 2012 Our purpose in the study was to investigate the effects of down-regulation of CD44 or CD147 on the metastatic ability of prostate cancer (CaP) cells, their docetaxel (DTX) responsiveness and potential mechanisms involved in vitro and in vivo. Docetaxel 156-165 CD44 molecule (Indian blood group) Homo sapiens 78-82 22870202-9 2012 Our results indicated that KD of CD44 or CD147 decreased MCT4 and MRP2 expression, reduced CaP proliferation and invasive potential and enhanced DTX sensitivity; and KD of CD44 or CD147 down-regulated p-Akt and p-Erk, the main signal modulators associated with cell growth and survival. Docetaxel 145-148 CD44 molecule (Indian blood group) Homo sapiens 33-37 22870202-9 2012 Our results indicated that KD of CD44 or CD147 decreased MCT4 and MRP2 expression, reduced CaP proliferation and invasive potential and enhanced DTX sensitivity; and KD of CD44 or CD147 down-regulated p-Akt and p-Erk, the main signal modulators associated with cell growth and survival. Docetaxel 145-148 CD44 molecule (Indian blood group) Homo sapiens 172-176 22870202-10 2012 In vivo, CD44 or CD147-KD PC-3M-luc xenografts displayed suppressed tumor growth with increased DTX responsiveness compared to control xenografts. Docetaxel 96-99 CD44 molecule (Indian blood group) Homo sapiens 9-13 27473554-0 2016 Fabrication and biological evaluation of chitosan coated hyaluronic acid-docetaxel conjugate nanoparticles in CD44(+) cancer cells. Docetaxel 73-82 CD44 molecule (Indian blood group) Homo sapiens 110-114 27473554-8 2016 Chitosan coated hyaluronic acid-docetaxel conjugate nanoparticles fabricated and evaluated in CD44+ cancer cells. Docetaxel 32-41 CD44 molecule (Indian blood group) Homo sapiens 94-98 24659820-13 2014 Before docetaxel exposure, a selected CD44(+) subpopulation of PC-3 cells exhibited EMT phenotype and intrinsic docetaxel resistance; ZEB1/CD44(+) subpopulations were found in tumor cell lines and primary tumors; this correlated with aggressive clinical behavior. Docetaxel 112-121 CD44 molecule (Indian blood group) Homo sapiens 38-42 23715169-7 2013 Thereafter, in the scaffold model, we found that the chemotherapeutic regimen of docetaxel, cisplatin and fluorouracil unleashed a stronger capability than the regimen comprising cisplatin and fluorouracil to deplete the CD44(+) subpopulation. Docetaxel 81-90 CD44 molecule (Indian blood group) Homo sapiens 221-225 23368632-4 2013 Anticancer drugs 5FU, docetaxel, cisplatin, and carboplatin were seen to inhibit growth of the CD44+CD117+ cells by 50% in the 2D culture with IC50 concentration, whereas, in the 3D culture, the four drugs inhibited the cell growth by only 34.4%, 40.8%, 34.8% and 21.9% at 3D one, respectively. Docetaxel 22-31 CD44 molecule (Indian blood group) Homo sapiens 95-99 23301003-7 2013 Histological analysis revealed that areas showing high R(2)* values in docetaxel-treated FTH-BCSC tumors by MRI contained EGFP+/FTH+ viable cell populations with high percentages of CD44+/CD24- cells. Docetaxel 71-80 CD44 molecule (Indian blood group) Homo sapiens 182-186 21733572-7 2011 The nanoparticles were shown to be taken up by the HA-CD44 interaction according to DCT and coumarin 6 (C6) cellular uptake studies. Docetaxel 84-87 CD44 molecule (Indian blood group) Homo sapiens 54-58 21139802-10 2010 CD44v7-10 RNAi in PC-3M cells caused marked sensitization to Docetaxel; the 2 CD44s re-expression approaches caused minimal sensitization. Docetaxel 61-70 CD44 molecule (Indian blood group) Homo sapiens 0-4 21376257-12 2011 After cisplatin and docetaxel treatment with the same drug concentration, CD44+ cells showed a higher survival rate compared with CD44- cells. Docetaxel 20-29 CD44 molecule (Indian blood group) Homo sapiens 74-78 21376257-12 2011 After cisplatin and docetaxel treatment with the same drug concentration, CD44+ cells showed a higher survival rate compared with CD44- cells. Docetaxel 20-29 CD44 molecule (Indian blood group) Homo sapiens 130-134 19666588-6 2009 Both CD44(+)/CD24(-/low)-MS and claudin-low signatures were more pronounced in tumor tissue remaining after either endocrine therapy (letrozole) or chemotherapy (docetaxel), consistent with the selective survival of tumor-initiating cells posttreatment. Docetaxel 162-171 CD44 molecule (Indian blood group) Homo sapiens 5-9 20074368-9 2010 CD44v7-10 RNAi in PC-3M cells caused marked sensitization to Docetaxel; the two CD44s re-expression approaches caused minimal sensitization. Docetaxel 61-70 CD44 molecule (Indian blood group) Homo sapiens 0-4 20179163-5 2010 In contrast, the docetaxel treatment induced significant antiproliferative and apoptotic effects on the CD133(-)/CD44(low)/AR(+) non-SP cell fraction isolated from the WPE1-NB26 cell line. Docetaxel 17-26 CD44 molecule (Indian blood group) Homo sapiens 113-117 34970839-0 2022 Comparative proteome analysis identified CD44 as a possible serum marker for docetaxel resistance in castration-resistant prostate cancer. Docetaxel 77-86 CD44 molecule (Indian blood group) Homo sapiens 41-45 9499461-2 1998 Docetaxel, in a low concentration range (1-3x10-9 M), increased the expression of the adhesion molecules LFA-3, ICAM-1, CD44s, CD44v6, CD15, CD13 and VLA-4/5/6 on the tumor cells. Docetaxel 0-9 CD44 molecule (Indian blood group) Homo sapiens 120-124 34970839-11 2022 We determined serum levels of five (CD44, MET, GSN, IL13RA2 and LNPEP) proteins in serum samples of DOC-treated patients and found high CD44 serum levels to be independently associated with poor overall survival (p = 0.001). Docetaxel 100-103 CD44 molecule (Indian blood group) Homo sapiens 36-40 34970839-11 2022 We determined serum levels of five (CD44, MET, GSN, IL13RA2 and LNPEP) proteins in serum samples of DOC-treated patients and found high CD44 serum levels to be independently associated with poor overall survival (p = 0.001). Docetaxel 100-103 CD44 molecule (Indian blood group) Homo sapiens 136-140 34236115-0 2021 Effects of miR-224-5p-enhanced downregulation of pannexin-1 on docetaxel-induced apoptosis in amoeboid-like CD44high oral cancer cells. Docetaxel 63-72 CD44 molecule (Indian blood group) Homo sapiens 108-112 34236115-4 2021 Amoeboid-like CD44high OSCC cells exhibited robust resistance to docetaxel-induced apoptosis and significant upregulation of miR-224-5p expression compared with epithelial-like CD44high OSCC cells and mesenchymal-like CD44high OSCC cells. Docetaxel 65-74 CD44 molecule (Indian blood group) Homo sapiens 14-18 32985018-7 2020 When pretreated with docetaxel, they readily differentiated into docetaxel-resistant CD44negative "bulk" cells, thus accounting for the microevolution of drug-resistant cell lineages. Docetaxel 21-30 CD44 molecule (Indian blood group) Homo sapiens 85-89 32985018-7 2020 When pretreated with docetaxel, they readily differentiated into docetaxel-resistant CD44negative "bulk" cells, thus accounting for the microevolution of drug-resistant cell lineages. Docetaxel 65-74 CD44 molecule (Indian blood group) Homo sapiens 85-89 32985018-8 2020 Combined docetaxel/fenofibrate treatment induced the generation of poly(morpho)nuclear giant cells and drug-resistant CD44high SCL cells. Docetaxel 9-18 CD44 molecule (Indian blood group) Homo sapiens 118-122 32985018-9 2020 However, the CD44negative offspring of docetaxel- and docetaxel/fenofibrate-treated SCLs remained relatively sensitive to the combined treatment, while retaining enhanced resistance to docetaxel. Docetaxel 39-48 CD44 molecule (Indian blood group) Homo sapiens 13-17 32985018-9 2020 However, the CD44negative offspring of docetaxel- and docetaxel/fenofibrate-treated SCLs remained relatively sensitive to the combined treatment, while retaining enhanced resistance to docetaxel. Docetaxel 54-63 CD44 molecule (Indian blood group) Homo sapiens 13-17 32985018-9 2020 However, the CD44negative offspring of docetaxel- and docetaxel/fenofibrate-treated SCLs remained relatively sensitive to the combined treatment, while retaining enhanced resistance to docetaxel. Docetaxel 54-63 CD44 molecule (Indian blood group) Homo sapiens 13-17 32985018-13 2020 However, docetaxel/fenofibrate-induced selective expansion of hyper-resistant CD44high SCL prostate cells and their "bulk" progenies prompts the microevolution of prostate tumor drug-resistance. Docetaxel 9-18 CD44 molecule (Indian blood group) Homo sapiens 78-82 32985018-17 2020 However, they also revealed the resistance of CD44+ prostate cancer stem cells to the combined docetaxel/fenofibrate treatment, accompanied by docetaxel/fenofibrate-induced microevolution of hyper-resistant CD44- progenies. Docetaxel 95-104 CD44 molecule (Indian blood group) Homo sapiens 46-50 32985018-17 2020 However, they also revealed the resistance of CD44+ prostate cancer stem cells to the combined docetaxel/fenofibrate treatment, accompanied by docetaxel/fenofibrate-induced microevolution of hyper-resistant CD44- progenies. Docetaxel 143-152 CD44 molecule (Indian blood group) Homo sapiens 207-211 32642575-3 2020 We hypothesized that CD44 in serum exosomes could be a diagnostic marker for docetaxel resistance in CRPC patients. Docetaxel 77-86 CD44 molecule (Indian blood group) Homo sapiens 21-25 30935014-0 2019 CD44 Promotes Migration and Invasion of Docetaxel-Resistant Prostate Cancer Cells Likely via Induction of Hippo-Yap Signaling. Docetaxel 40-49 CD44 molecule (Indian blood group) Homo sapiens 0-4 31273630-7 2020 RESULTS: The half-maximal inhibitory concentration (IC50) of DOC was 10 mug/ml after 48 h. Flow cytometry showed a significant increase in CD44+ cells after treatment with DOC (94.3%) when compared with non-treated cells (84.6%) (P < 0.01). Docetaxel 61-64 CD44 molecule (Indian blood group) Homo sapiens 139-143 31273630-7 2020 RESULTS: The half-maximal inhibitory concentration (IC50) of DOC was 10 mug/ml after 48 h. Flow cytometry showed a significant increase in CD44+ cells after treatment with DOC (94.3%) when compared with non-treated cells (84.6%) (P < 0.01). Docetaxel 172-175 CD44 molecule (Indian blood group) Homo sapiens 139-143 31273630-9 2020 CONCLUSION: DOC treatment affected CD44+ cell frequency in MKN-45 cell line and induced significant changes in the expression of SIRT1, CXCR4, miR-21, miR-451, and miR-34a that are implicated in stemness and chemo-radioresistance, which might offer new insights for future GC therapies. Docetaxel 12-15 CD44 molecule (Indian blood group) Homo sapiens 35-39 31273630-0 2020 Altered Expression of CD44, SIRT1, CXCR4, miR-21, miR-34a, and miR-451 Genes in MKN-45 Cell Line After Docetaxel Treatment. Docetaxel 103-112 CD44 molecule (Indian blood group) Homo sapiens 22-26 31273630-2 2020 The aim of this study was to investigate the effect of docetaxel (DOC) treatment on CD44+ cell frequency in human gastric cancer (GC) MKN-45 cell line and its effect on expression levels of SIRT1, CXCR4, microRNA (miR)-21, miR-451, and miR-34a that are closely correlated with the chemoresistance or self-renewal of cancer stem cells (CSCs). Docetaxel 55-64 CD44 molecule (Indian blood group) Homo sapiens 84-88 31273630-2 2020 The aim of this study was to investigate the effect of docetaxel (DOC) treatment on CD44+ cell frequency in human gastric cancer (GC) MKN-45 cell line and its effect on expression levels of SIRT1, CXCR4, microRNA (miR)-21, miR-451, and miR-34a that are closely correlated with the chemoresistance or self-renewal of cancer stem cells (CSCs). Docetaxel 66-69 CD44 molecule (Indian blood group) Homo sapiens 84-88 30993586-10 2020 In addition, the combination of apigenin treatment and MK silencing showed better outcomes on the anticancer efficacy of docetaxel in CD44+CD133+ PC3 cells. Docetaxel 121-130 CD44 molecule (Indian blood group) Homo sapiens 134-138 32223952-0 2020 Frequency of CD44 positive cells in MKN45 cell line after treatment with docetaxel in two and three-dimensional cell cultures. Docetaxel 73-82 CD44 molecule (Indian blood group) Homo sapiens 13-17 32223952-4 2020 In this study the quantity of CD44+ cells in MKN-45 cell line in response to half maximal inhibitory concentration (IC50) dose of Docetaxel (DOC) was measured in 2D and 3D cultures. Docetaxel 130-139 CD44 molecule (Indian blood group) Homo sapiens 30-34 32223952-4 2020 In this study the quantity of CD44+ cells in MKN-45 cell line in response to half maximal inhibitory concentration (IC50) dose of Docetaxel (DOC) was measured in 2D and 3D cultures. Docetaxel 141-144 CD44 molecule (Indian blood group) Homo sapiens 30-34 30935014-12 2019 CD44 promotes migration and invasion of docetaxel-resistant PCa cells probably via induction of Hippo-Yap signaling pathway and CD44/YAP pathway may be a therapeutic target for docetaxel-resistant PCa. Docetaxel 40-49 CD44 molecule (Indian blood group) Homo sapiens 0-4 30935014-12 2019 CD44 promotes migration and invasion of docetaxel-resistant PCa cells probably via induction of Hippo-Yap signaling pathway and CD44/YAP pathway may be a therapeutic target for docetaxel-resistant PCa. Docetaxel 40-49 CD44 molecule (Indian blood group) Homo sapiens 128-132 30935014-12 2019 CD44 promotes migration and invasion of docetaxel-resistant PCa cells probably via induction of Hippo-Yap signaling pathway and CD44/YAP pathway may be a therapeutic target for docetaxel-resistant PCa. Docetaxel 177-186 CD44 molecule (Indian blood group) Homo sapiens 0-4 30935014-12 2019 CD44 promotes migration and invasion of docetaxel-resistant PCa cells probably via induction of Hippo-Yap signaling pathway and CD44/YAP pathway may be a therapeutic target for docetaxel-resistant PCa. Docetaxel 177-186 CD44 molecule (Indian blood group) Homo sapiens 128-132 32254339-0 2018 Reduction-responsive core-crosslinked hyaluronic acid-b-poly(trimethylene carbonate-co-dithiolane trimethylene carbonate) micelles: synthesis and CD44-mediated potent delivery of docetaxel to triple negative breast tumor in vivo. Docetaxel 179-188 CD44 molecule (Indian blood group) Homo sapiens 146-150 30148955-3 2018 Here, we propose double-layered polymeric NPs for the delivery of the chemotherapeutic docetaxel (DTX) and the photosensitizer disulfonate tetraphenyl chlorin (TPCS2a) coated with hyaluronic acid (HA), which allows cell targeting via CD44 receptors. Docetaxel 98-101 CD44 molecule (Indian blood group) Homo sapiens 234-238 28859899-0 2017 Combination of using prodrug-modified cationic liposome nanocomplexes and a potentiating strategy via targeted co-delivery of gemcitabine and docetaxel for CD44-overexpressed triple negative breast cancer therapy. Docetaxel 142-151 CD44 molecule (Indian blood group) Homo sapiens 156-160 29190901-6 2017 We found that the expression of KIF11 was significantly increased in CD44+/CD24- subpopulation of docetaxel resistant TNBC cells. Docetaxel 98-107 CD44 molecule (Indian blood group) Homo sapiens 69-73 29029419-8 2017 In addition, CD44 inhibitor could decrease glucose consumption and increase ROS levels of PC-3 cells significantly, as well as sensitize PC-3 cells to docetaxel. Docetaxel 151-160 CD44 molecule (Indian blood group) Homo sapiens 13-17 28418843-11 2017 Also, in vitro cell studies show that CD44+/CD24+/high cells are more resistant to docetaxel, while CD44+/CD24-/low cells are resistant to doxorubicin. Docetaxel 83-92 CD44 molecule (Indian blood group) Homo sapiens 38-42